Mast Therapeutics Announces Pricing Of Underwritten Public Offering
The securities described above are being offered by
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Vepoloxamer is an investigational new drug being evaluated in a pivotal Phase 3 study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in a Phase 2 study for the treatment of patients with chronic heart failure. AIR001 is an investigational new drug in Phase 2a clinical development for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of
Forward Looking Statements
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mast-therapeutics-announces-pricing-of-underwritten-public-offering-300218048.html
Mast Therapeutics, Ioana C. Hone (email@example.com), 858-552-0866 Ext. 303